Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2022 | Updates on neuromodulation for Alzheimer’s disease

Lars Wojtecki, MD, PhD, Institute of Clinical Neuroscience and Medical Psychology, University Düsseldorf, Düsseldorf, Germany, shares the latest developments in neuromodulation for Alzheimer’s disease. The focus is now on evaluating transcranial pulse stimulation (TPS) in controlled trials, understanding the electrophysiological changes and mechanisms of action, and identifying the best stimulation patterns for dementia patients. Other investigation areas focus on transcranial magnetic stimulation (TMS), the combination of TMS with simultaneous electroencephalography (EEG), and alternating current techniques with gamma stimulation. Additionally, deep brain stimulation (DBS) is also being evaluated in a multi-center clinical trial in patients with Alzheimer’s disease. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.


Grants/Institutional Support: Hilde Ulrichs Stiftung für Parkinsonforschung, ParkinsonFonds Deutschland, BMBF/ERA-NETNEURON, DFG Forschergruppe (FOR1328), Deutsche Parkinson Vereinigung (DPV), Forschungskommission, Medizinische Fakultät, HHU Düsseldorf, UCB; Medtronic, UCB, Teva, Allergan, Merz, Abbvie, Roche, Bial, Merck, Novartis, Desitin, Spectrum;
Honorary/Travel Grants/Consultancy: TEVA, UCB Schwarz, Desitin, Medtronic, Abbott/Abbvie, MEDA, Boehringer I, Storz Medical, Kyowa Kirin, Guidepoint, Merck, Merz, Synergia, BIAL, Zambon, Sapio Life, STADA, Inomed, Vertanical;
Stock Ownership: BioNTech.